Back to Sweden: 💥propensity matched study,>1200 pts 💥HFrEF+CrCl <30 💥with vs w/out RASi 💥Same analysis perf. in pts w/out severe CKD as ➕control 💥Outcome: mortality 💥Similar⬇️RR (21% v 24%) if treated with RASi for advanced CKD vs no advanced CKD
In HF with stage 4-5 CKD, use of RAS antagonists is associated with lower all-cause mortality. http://t.co/US0iDwmMEO
In HF with stage 4-5 CKD, use of RAS antagonists is associated with lower all-cause mortality. http://t.co/US0iDwmMEO
【クレアチニンクリアランス＜30mL/分でも，RA系抑制薬はHFrEFへの総死亡抑制か。HR 0.76 [95%CI 0.67 - 0.86]。腎機能正常例よりは相対リスク減少率小：傾向スコアマッチ1204例比較】 EHJ http://t.co/bC2hYXXJrs